Many orally administered phenolic drugs undergo enterohepatic recycling (EHR), presumably mediated by the hepatic phase II enzymes. However, the disposition of extrahepatically generated phase II metabolites is unclear. This paper aims to determine the new roles of liver and intestine in the disposition of oral phenolics. Sixteen representative phenolics were tested using direct portal vein infusion and/or intestinal perfusion. The results showed that certain glucuronides were efficiently recycled by liver. OATP1B1/1B3/2B1 were the responsible uptake transporters. Hepatic uptake is the rate-limiting step in hepatic recycling. Our findings showed that the disposition of many oral phenolics is mediated by intestinal glucuronidation and hepatic recycling. A new disposition mechanism ‘Hepatoenteric Recycling (HER)”, where intestine is the metabolic organ and liver is the recycling organ, was revealed. Further investigations focusing on HER should help interpret how intestinal aliments or co-administered drugs that alter gut enzymes (e.g. UGTs) expression/activities will impact the disposition of phenolics.
A full-term pregnancy has been associated with reduced risk for developing breast cancer. In rodent models, the protective effect of pregnancy can be mimicked with a defined regimen of estrogen and progesterone combination (E/P). However, the effects of pregnancy levels of E/P in humans and their underlying mechanisms are not fully understood. In this report, we investigated the growth inhibitory effects of pregnancy levels of E/P and both natural and synthetic retinoids in an immortalized human mammary epithelial cell line, 76N TERT cell line. We observed that cell growth was modestly inhibited by E/P, 9-cis-retinoic acid (9-cis RA) or all-trans-retinoic acid (ATRA), and strongly inhibited by N-(4-hydroxyphenyl) retinamide (HPR). The growth inhibitory effects of retinoids were further increased in the presence of E/P, suggesting their effects are additive. In addition, our results showed that both E/P and retinoid treatments resulted in increased RARE and p53 gene activity. We further demonstrated that p53 and p21 protein expression were induced following the E/P and retinoid treatments. Furthermore, we demonstrated that while the telomerase activity was moderately inhibited by E/P, 9-cis RA and ATRA, it was almost completely abolished by HPR treatment. These inhibitions on telomerase activity by retinoids were potentiated by co-treatment with E/P, and correlated well with their observed growth inhibitory effects. Finally, this study provides the first evidence that estrogen receptor beta is up-regulated in response to E/P and retinoid treatments. Taken together, our studies show that part of the anti-growth effects of E/P and retinoids is p53 dependent, and involve activation of p53 and subsequent induction of p21 expression. Inhibition of telomerase activity and up-regulation of estrogen receptor beta are also associated with the E/P- and retinoid-mediated growth inhibition. Our studies also demonstrate that the potency of retinoids on cell growth inhibition may be increased through combination of estrogen and progesterone treatment.
147 Background: Communication with patients about their health care is vital to the physician-patient relationship. This is especially true in oncology where patients receive frequent diagnostic evaluations and their diseases are often active and evolving. In 2009, as part of “meaningful use”, Congress mandated the need to establish an electronic portal for patient communication. We studied factors associated with the use of our online patient portal. Methods: We performed a retrospective chart review of the use of our EMR online portal, MyChart. We assessed whether patients were informed of the existence of the portal and if they had activated and used it. We analyzed whether disparities in age, gender, rural or urban residence, or income impacted patients’ use of this feature. Results: Between January 1, 2014 and December 31, 2015, 1947 patients were seen in the Hematology Oncology Clinic at St. Louis University Hospital. 508 (26.1%) had activated and used MyChart and 1437 (73.9%) had not. Of 1437 patients who had not used MyChart, 110 (7.6%) had not been given the code, 1316 (91.5%) had been given the code but had not activated it, and 13 (0.9%) had declined the code. Patients who activated MyChart were more likely to be less than 65 years old (60.0% vs 40.0% p < .0.0001). Patients who did not activate it were more likely to live in a ZIP code where the median annual income was below the state median, a surrogate for lower income (84.8% vs 15.2%, p < 0.0001). Use of MyChart was not statistically associated with gender or with residence in an urban versus rural location. Conclusions: A large majority of patients in our urban, academic oncology clinic did not access the online communication portal. Use was associated with younger age, and lack of use was associated with residence in a lower income ZIP code. There was no association between use and gender or residence in an urban versus rural location. Future work will attempt to improve provider-patient communication through increasing access to the portal.
Hepatoma Research is an open access journal and focuses on all topics related to hepatoma. The following articles are especially welcome: pathogenesis, clinical examination and early diagnosis of hepatoma, complications of hepatoma, and their preventions and treatments, etc.